JOP20220113A1 - طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم - Google Patents

طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم

Info

Publication number
JOP20220113A1
JOP20220113A1 JOP/2022/0113A JOP20220113A JOP20220113A1 JO P20220113 A1 JOP20220113 A1 JO P20220113A1 JO P20220113 A JOP20220113 A JO P20220113A JO P20220113 A1 JOP20220113 A1 JO P20220113A1
Authority
JO
Jordan
Prior art keywords
syndrome
cls
ips
methods
treating
Prior art date
Application number
JOP/2022/0113A
Other languages
English (en)
Inventor
Thomas A Dudler
Gregory A Demopulos
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of JOP20220113A1 publication Critical patent/JOP20220113A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • G01N2800/245Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Environmental Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)

Abstract

يتعلق الاختراع الحالي، في أحد جوانبه، بتقديم طرق لتثبيط تأثيرات تنشيط المكمل المعتمد على MASP 2 في مريض من البشر يعاني من، أو مُعرَّض لخطر تطوُّر، HSCT-IPS و/ أو يعاني من، أو مُعرَّض لخطر تطوُّر، HSCT-CLS و/ أو يعاني من، أو مُعرَّض لخطر تطوُّر، HSCT-FO و/ أو يعاني من، أو مُعرَّض لخطر تطوُّر، HSCT-ES. تتضمن الطرق خطوة إعطاء، إلى مريض بحاجة إلى ذلك، كمية من عامل التثبيط MASP 2 تكون فعالة في تثبيط تنشيط المكمل المعتمد على MASP 2.
JOP/2022/0113A 2019-11-26 2020-11-24 طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم JOP20220113A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940735P 2019-11-26 2019-11-26
US201962940720P 2019-11-26 2019-11-26
PCT/US2020/062082 WO2021108447A1 (en) 2019-11-26 2020-11-24 Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant

Publications (1)

Publication Number Publication Date
JOP20220113A1 true JOP20220113A1 (ar) 2023-01-30

Family

ID=76130747

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0113A JOP20220113A1 (ar) 2019-11-26 2020-11-24 طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم

Country Status (13)

Country Link
US (1) US20220064330A1 (ar)
EP (1) EP4065165A1 (ar)
JP (1) JP2023503611A (ar)
KR (1) KR20220104201A (ar)
CN (1) CN115335077A (ar)
AU (1) AU2020391175A1 (ar)
BR (1) BR112022010078A2 (ar)
CA (1) CA3159152A1 (ar)
CL (1) CL2022001355A1 (ar)
IL (1) IL293363A (ar)
JO (1) JOP20220113A1 (ar)
MX (1) MX2022006334A (ar)
WO (1) WO2021108447A1 (ar)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR102564616B1 (ko) * 2016-01-05 2023-08-08 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
CN109414441A (zh) * 2016-06-27 2019-03-01 艾其林医药公司 治疗医学障碍的喹唑啉和吲哚化合物
WO2018075484A1 (en) * 2016-10-17 2018-04-26 Medical University Of South Carolina Compositions and methods for treating and preventing transplant-associated injury
CR20190468A (es) * 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
US20200369763A1 (en) * 2017-12-01 2020-11-26 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same

Also Published As

Publication number Publication date
AU2020391175A1 (en) 2022-07-07
BR112022010078A2 (pt) 2022-12-13
JP2023503611A (ja) 2023-01-31
MX2022006334A (es) 2022-06-22
IL293363A (en) 2022-07-01
CL2022001355A1 (es) 2023-05-19
EP4065165A1 (en) 2022-10-05
US20220064330A1 (en) 2022-03-03
CN115335077A (zh) 2022-11-11
KR20220104201A (ko) 2022-07-26
CA3159152A1 (en) 2021-06-03
WO2021108447A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
MY197758A (en) Methods for treating conditions associated with masp-2 dependent complement activation
MX2023007754A (es) Una composicion que comprende un anticuerpo inhibidor de masp-2 para su uso en el tratamiento de la nefropatia por inmunoglobulina a (igan) dependiente de esteroides.
PH12020500276A1 (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
ECSP20082339A (es) Moduladores de la expresión de apol1
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation
JOP20220113A1 (ar) طرق لعلاج و/ أو منع متلازمة الالتهاب الرئوي مجهول السبب (ips) و/ أو متلازمة التسرب الشعري (cls) و/ أو متلازمة التطعيم (es) و/ أو زيادة حِمْل المائع (fo) المصاحبة لزرع الخلايا الجذعية المكونة للدم
MX2022010960A (es) Métodos y composiciones para tratar el trastorno por uso de cannabis y mitigar la abstinencia de cannabinoides.
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical
MX2022007453A (es) Potenciacion de tratamiento contra helmintos.
ZA202102023B (en) Potentiation of helminth treatment
ECSP20016283A (es) Métodos para tratar y/o prevenir la enfermedad del injerto frente a hospedador y/o hemorragia alveolar y/o enfermedad veno-oclusiva asociada a trasplante de células madre hematopoyéticas
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств